Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Travere Therapeutics Provides Regulatory Updates On Its Development Programs

PDUFA target action date for NDA for sparsentan in IgAN on-track for November 17, 2022   Company to utilize traditional approval process for sparsentan in FSGS following completion of the pivotal Phase 3 DUPLEX
byBenzinga Newsdesk
August 3, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

PDUFA target action date for NDA for sparsentan in IgAN on-track for November 17, 2022

 

Company to utilize traditional approval process for sparsentan in FSGS following completion of the pivotal Phase 3 DUPLEX Study in 2023

Company and its partner Vifor Pharma applying for conditional marketing authorization of sparsentan for IgAN in Europe; review decision expected in second half of 2023

Pegtibatinase granted Breakthrough Therapy Designation by FDA

Company to host conference call and webcast tomorrow at 8:00 a.m. ET

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

PHX Minerals To Sell Additional Legacy Assets; Entered Into Two Agreements With Separate Buyers To Sell 257 Non-operated Legacy Working Interest Wellbores In The Arkoma Basin And The Eagleford Play For Total Cash Consideration Of ~$10.7M

By Benzinga Newsdesk
December 27, 10:16 AM
Sale of 257 non-operated legacy working interest wellbores for $10.7 million, advances strategy of high-grading Company's asset base to further fixed-cost royalty production model FORT WORTH,

PHX